| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 10/05/2004 | US6800625 For therapy of sexual dysfunction |
| 10/05/2004 | US6800620 Contacting leukocytes, osteoclasts with an enzyme inhibitors, a 9h-purin-3h-quinazolin-4-one derivatives, treating bone-resorption disorder, antiproliferative agents treating leukemia cells |
| 10/05/2004 | US6800619 Urea heterocycliccarbonyl-substituted aspartic or glutamic acid derivatives |
| 10/05/2004 | US6800612 Have vasodilating activity and inhibit the aggregation of the platelets; releasing no |
| 10/05/2004 | US6800461 The b-domain of the wild-type factor viii cdna has been deleted and a truncated factor ix intron 1 has been inserted in one or more locations of the factor viii cdna; vector for human gene therapy |
| 09/30/2004 | WO2004083250A1 Construct comprising recognition domain of antibody against von willebrand factor-specific cleaving enzyme |
| 09/30/2004 | WO2004083184A1 Receptor antagonist |
| 09/30/2004 | WO2004083174A2 Sulfonyl-amidino containing and tetrahydropyrimidino containing compounds as factor xa inhibitors |
| 09/30/2004 | WO2004082720A1 Drug for treating hemophilia and method of treating hemophilia using the same |
| 09/30/2004 | WO2004082708A2 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
| 09/30/2004 | WO2004082702A1 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy |
| 09/30/2004 | WO2004082694A1 Cell therapy material and intravascular therapy method |
| 09/30/2004 | WO2004082574A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d5 (drd5) |
| 09/30/2004 | WO2004082573A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4) |
| 09/30/2004 | WO2004082567A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d1a (drd1) |
| 09/30/2004 | WO2004038405A3 Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) |
| 09/30/2004 | WO2004028564A3 Treatment of pathologies which escape the immune response, using optimised antibodies |
| 09/30/2004 | WO2003087333A8 Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| 09/30/2004 | US20040192961 such as 2-nitrophenol by reacting 3-hydroxy-4-methoxybenzophenone with alkyl nitrate in presence of regioselective acid catalyst (sulfuric acid) |
| 09/30/2004 | US20040192775 Stable carnitine or carnitine acetyl ester; dietetics, nutraceutine, drugs |
| 09/30/2004 | US20040192774 Method for improving the well-being of poultry by in-ovo injection of carnitine |
| 09/30/2004 | US20040192746 Anticancer agents; central nervous system disorders; sexual disorders; antidiabetic agents; obesity; muscular disorders; alopecia; sepsis; autoimmune disease |
| 09/30/2004 | US20040192702 Heteroaryl alkyl piperazine derivatives |
| 09/30/2004 | US20040192673 Obesity, non-insulin-dependent diabetes,strokes, sleep disorders; antiischemic and antiemetic agents |
| 09/30/2004 | US20040192670 For inhibiting bone resorption, treating/preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, aniogenesis, atherosclerosis, arthritis, tumor growth and metastasis |
| 09/30/2004 | US20040192661 Micronized eplerenone compositions |
| 09/30/2004 | US20040192648 Peritoneal dialysis solution containing modified icodextrins |
| 09/30/2004 | US20040192596 Therapeutic fibrin-derived peptides and uses thereof |
| 09/30/2004 | US20040191230 Pharmaceutical composition for the diagnosis, prevention or treatment of a tumoral pathology comprising an agent modulating the polymerization state of actin |
| 09/30/2004 | US20040191210 Compounds |
| 09/30/2004 | US20040191190 Cosmetic and/or pharmaceutical preparations containing plant extracts |
| 09/30/2004 | DE10202468A1 Pteridinderivate, Verfahren zu deren Herstellung und ihre Verwendung Pteridine derivatives, processes for their preparation and their use |
| 09/30/2004 | CA2790689A1 Fvii or fviia variants |
| 09/30/2004 | CA2519258A1 Construct comprising region recognized by antibody against von willebrand factor-specific cleaving protease |
| 09/30/2004 | CA2518327A1 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
| 09/30/2004 | CA2517191A1 Use of low molecular weight thrombin inhibitors in cholesterol-lowering therapy |
| 09/29/2004 | EP1462449A1 Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha levels |
| 09/29/2004 | EP1462109A1 Hemostatic, emollient and lubricating preparations containing pork fat extract (lard) |
| 09/29/2004 | EP1462108A1 Interferon g (g) production promoter |
| 09/29/2004 | EP1461614A2 Functional inactivation of cxcr4-mediated responses in growth hormone transgenic mice through socs3 upregulation |
| 09/29/2004 | EP1461610A2 Heme-regulated eukaryotic initiation factor 2 alpha kinase knockout mice and methods for use |
| 09/29/2004 | EP1461443A2 Carbohydrate-associated proteins |
| 09/29/2004 | EP1461339A2 Spiroazacyclic compounds as monoamine receptor modulators |
| 09/29/2004 | EP1461337A1 Pyrido[2,1-a]isoquinoline derivatives as dpp-iv inhibitors |
| 09/29/2004 | EP1461336A2 1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists |
| 09/29/2004 | EP1461323A2 Compounds for the treatment of metabolic disorders |
| 09/29/2004 | EP1461321A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 09/29/2004 | EP1461165A1 Metallic structures incorporating bioactive materials and methods for creating the same |
| 09/29/2004 | EP1461092A1 Process for coating a surface of a stent |
| 09/29/2004 | EP1461065A1 Erythropoietin dosing regimen for treating anemia |
| 09/29/2004 | EP1461053A2 Storage-stable fibrin sealant |
| 09/29/2004 | EP1461049A1 Use of sulfated glycosaminoglycans for establishing effective labor in women |
| 09/29/2004 | EP1461039A1 Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor |
| 09/29/2004 | EP1461021A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts |
| 09/29/2004 | EP1460999A2 Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof |
| 09/29/2004 | EP1460996A2 Novel-n-4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa |
| 09/29/2004 | EP1419171A4 Methods for purification of an activated peg solution and for the synthesis of a modified hemoglobin solution |
| 09/29/2004 | EP1292288B1 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury |
| 09/29/2004 | EP1202959B1 Aminobenzophenones as inhibitors of il-1-beta and tnf-alpha |
| 09/29/2004 | EP1200400B1 Substituted pyrrolidin-2,3,4-trion derivatives useful as nmda-receptor antagonists |
| 09/29/2004 | EP1189881B1 Propanoic acid derivatives that inhibit the binding of integrins to their receptors |
| 09/29/2004 | EP1012140B1 New amidino derivatives and their use as thrombin inhibitors |
| 09/29/2004 | EP1003503B1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 09/29/2004 | CN1533387A 1-phenysulfonyl-1,3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use |
| 09/29/2004 | CN1533374A Substitutled cyclohexane-1,4-diamine derivatives |
| 09/29/2004 | CN1531941A Medicine granule Tediankang for treating purpura and preparing method |
| 09/29/2004 | CN1168738C Biotin derivatives |
| 09/29/2004 | CN1168715C Novel benzene amine compound, its prepn. process and medicinal compsns. contg. them |
| 09/29/2004 | CN1168711C Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
| 09/29/2004 | CN1168498C Child 'xuebao' chewing tablet and preparing process thereof |
| 09/29/2004 | CN1168492C Use of activated protein C in porducing medicine and unit formulation containing activated protein C |
| 09/29/2004 | CN1168484C Medicine for treating leukopenia caused by carcinosis radiotherapy and chemotherapy and its preparing method |
| 09/28/2004 | US6797811 Antibodies to chemokine receptor 88C |
| 09/28/2004 | US6797806 Multimeric proteins;for diagnosis and therapy of disorders involving complement activity (globulins) and various inflammatory and immune disorders |
| 09/28/2004 | US6797718 Ether substituted imidazopyridines |
| 09/28/2004 | US6797716 Imidazonaphthyridines |
| 09/28/2004 | US6797713 1,4 substituted piperazines, 1,4 substituted piperidines, and 1-substituted,4-alkylidenyl piperidine compounds; dual acting molecules having both leukotriene inhibition properties |
| 09/28/2004 | US6797710 Cardiovascular disorders; serine protease inhibitor; administering by mouth; bioavailability |
| 09/28/2004 | US6797499 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof |
| 09/28/2004 | US6797285 Leaves of Cajanus Cajan(L.) Millsp and extract, formulation and uses thereof |
| 09/28/2004 | CA2167268C Anti-angiogenic compositions and methods of use |
| 09/23/2004 | WO2004081048A1 Ligand having agonistic activity to mutated receptor |
| 09/23/2004 | WO2004081016A1 Polymorphs and amorphous form of (s) - (+) -clopidogrel bisulfate |
| 09/23/2004 | WO2004080970A1 Novel bicyclic aromatic compounds, the production and use thereof in the form of drugs |
| 09/23/2004 | WO2004080485A1 Preventive/remedy for diseases in upper digestive tract |
| 09/23/2004 | WO2003105561A3 Method and devices for diagnosing and treating choroid plexus failure |
| 09/23/2004 | WO2003011219A3 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 09/23/2004 | US20040186277 Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of ion-exchange chromatography |
| 09/23/2004 | US20040186178 Amidino compounds useful as nitric oxide synthase inhibitors |
| 09/23/2004 | US20040186145 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 09/23/2004 | US20040186134 Inhibitors of Factor Xa are useful as anticoagulants in the treatment of cardiovascular disorders associated with thromboses; e.g., 1,1-dimethylethyl 1-[1-(-2-(-3-[2-(5-Chloro-thiophen-2-yl)-ethenesulfonylamino]-2-oxo-piperidin-1-yl)-acetyl)-pyrrolidin-2- yl-methyl]-pyrrolidin-3-yl}-methyl-carbamate |
| 09/23/2004 | US20040186127 E.g., 7-(5-(2-(cyclohexylmethylamino)ethyl)indol-2-yl), 2-methyl-3H-imidazo(4,5-b)pyridine; antiinflammatory agents; antiproliferative agents; autoimmune diseases; reperfusion injuries; osteoporosis; bone disorders; antimetastasis agents |
| 09/23/2004 | US20040186106 such as (S)-N-{{(1R, 2R)-2-{4-{[2-(4-Methyl-piperazin-1-yl)-benzimidazol-1-yl]methyl}-phenyl}-cyclohex-1-yl} carbonyl}-phenylglycinamide; for treatment of ischemic brain disorders |
| 09/23/2004 | US20040186090 New amidino derivatives and their use as thrombin inhibitors |
| 09/23/2004 | US20040186053 Having a molecular weight of about 72 kDa, being a single chain protein with an N-terminal amino acid sequence of Leu Ala Pro Ser Pro Gln Ser Pro Glu Thr 1 5 10 Pro Ala [SEQ ID NO:16], and producing rapid inhibition of factor Xa in the presence of protein Z, calcium ions and cephalin. |
| 09/23/2004 | US20040186048 Gene regulation therapy involving ferritin |
| 09/23/2004 | US20040185546 enzyme inhibitor for selectin mediated binding events and methods of treating disease conditions using animal models; genetic engineering |
| 09/23/2004 | US20040185122 Selective COX-2 inhibition from edible plant extracts |
| 09/23/2004 | DE10310278A1 New N-(benzazinyl)-(hetero)aralkylamine derivatives, are inhibitors of factor Xa and/or related serine proteases, useful e.g. as antithrombotic agents and intermediates |
| 09/22/2004 | EP1460074A1 Substituted amino alkyl compounds |